Cooperative Agreement R43CA221485

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $170,640 to the Dana-Farber Cancer Institute in Massachusetts to support research into the role of histone cleavage in breast cancer. The project aims to investigate how the histone demethylase KDM4C drives tumor growth in triple-negative breast cancer, a subtype with high treatment resistance and metastasis risk. Key objectives include determining if KDM4C prevents proteolytic...

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. The $1,944,610 award, which began on April 1, 2025 and will run through March 31, 2028, was granted to the Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research institution in New York. The research involves a...

Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...

Federal Grant Award Summary Natsar Pharmaceuticals, Inc. received a $1.63 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to advance the development and commercialization of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) for treating triple-negative breast cancer (TNBC). The award, obligated on September 22, 2025, with a completion date of August 31, 2027, supports the continued development of this...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $631,492 to support research at the University of Kentucky Research Foundation aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new target to treat triple-negative breast cancer (TNBC). The 5-year project, awarded on April 7, 2025 and scheduled for completion by March 31, 2030, will: Define how NNMT promotes anchorage-independent growth and protects TNBC cells...

Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $398,544 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on April 8, 2026, with completion targeted for March 31, 2028. This award funds pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, to address therapy-resistant triple-negative breast cancer (TNBC). The research will characterize molecular mechanisms...

The Case Western Reserve University will receive $1,168,656 in funding from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "FADD: A MECHANISTIC BASIS AND THERAPEUTIC OPPORTUNITY FOR OVERCOMING CDK4/6 INHIBITOR RESISTANCE" from April 1, 2023 to March 31, 2026. Through this three-year Project Grant, Case Western Reserve University researchers will investigate mechanisms of resistance to...

The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...

Federal Project Grant Award Summary The National Cancer Institute awarded a $403,686 Project Grant to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on April 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The research project, titled "Discerning the Role of CDK10 in Driving Aggressiveness and Disparities of Triple Negative Breast Cancer," will be conducted through March 31, 2028, at the awardee's Cleveland, Ohio...